The selective delivery of chemotherapeutic agents to their site of action should increase therapeutic effectiveness and limit side effects. Most drug therapies currently available, however, exhibit little, if any specificity. Many times, a drug has limited or no access to its intended site of action or is prematurely metabolized or excreted. In other instances, the drug travels rather freely throughout the body and not only acts on the desired target tissues but also causes undesirable effects on nontarget tissues. This lack of target specificity is attributable, for the most part, to the formidable barriers that the body presents to the successful delivery of a drug from its site of administration to its site of action: a drug normally encounters or must by pass various molecules, enzymes, cells, membranes, and organs before reaching its designated target.
This report aims to provide a comprehensive presentation of the global market for Site-Specific Drug Delivery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Site-Specific Drug Delivery. This report contains market size and forecasts of Site-Specific Drug Delivery in global, including the following market information:
- Global Site-Specific Drug Delivery Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Site-Specific Drug Delivery market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Site-Specific Drug Delivery in US$ by following Product Segments.: Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel and other.
Company profiles are primarily based on public domain information including company
- Johnson & Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
We surveyed the Site-Specific Drug Delivery companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Site-Specific Drug Delivery Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Site-Specific Drug Delivery Market Segment Percentages, by Type, 2022 (%)
- Liposomal Doxorubicin
- Liposomal Amphoteracin B
- Liposomal Paclitaxel
- Other
Global Site-Specific Drug Delivery Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Site-Specific Drug Delivery Market Segment Percentages, by Application, 2022 (%)
- Fungal Infection Therapy
- Cancer & Tumor Therapy
- Other
Global Site-Specific Drug Delivery Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Site-Specific Drug Delivery Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Site-Specific Drug Delivery revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Site-Specific Drug Delivery revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Johnson & Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
- Outline of Major Chapters:
- Chapter 1: Introduces the definition of Site-Specific Drug Delivery, market overview.
- Chapter 2: Global Site-Specific Drug Delivery market size in revenue.
- Chapter 3: Detailed analysis of Site-Specific Drug Delivery company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Site-Specific Drug Delivery in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: The main points and conclusions of the report.
